KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Operating Leases (2019 - 2026)

Pacira BioSciences has reported Operating Leases over the past 8 years, most recently at $33.7 million for Q1 2026.

  • For Q1 2026, Operating Leases fell 22.83% year-over-year to $33.7 million; the TTM value through Mar 2026 reached $33.7 million, down 22.83%, while the annual FY2025 figure was $36.2 million, 18.97% down from the prior year.
  • Operating Leases for Q1 2026 was $33.7 million at Pacira BioSciences, down from $36.2 million in the prior quarter.
  • Over five years, Operating Leases peaked at $77.7 million in Q1 2022 and troughed at $33.7 million in Q1 2026.
  • A 5-year average of $55.5 million and a median of $57.1 million in 2023 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: increased 11.57% in 2022 and later plummeted 30.36% in 2025.
  • Year by year, Operating Leases stood at $64.8 million in 2022, then decreased by 15.43% to $54.8 million in 2023, then dropped by 18.54% to $44.6 million in 2024, then decreased by 18.97% to $36.2 million in 2025, then fell by 6.83% to $33.7 million in 2026.
  • Business Quant data shows Operating Leases for PCRX at $33.7 million in Q1 2026, $36.2 million in Q4 2025, and $48.6 million in Q3 2025.